| Primary |
| Product Used For Unknown Indication |
18.3% |
| Decreased Appetite |
15.0% |
| Nausea |
13.3% |
| Muscle Spasticity |
8.3% |
| Impaired Gastric Emptying |
6.7% |
| Vomiting |
6.7% |
| Ill-defined Disorder |
5.0% |
| Breakthrough Pain |
3.3% |
| Drug Use For Unknown Indication |
3.3% |
| Pain |
3.3% |
| Adenocarcinoma Of The Cervix |
1.7% |
| Anxiety |
1.7% |
| Bowel Movement Irregularity |
1.7% |
| Brain Neoplasm |
1.7% |
| Cervix Carcinoma |
1.7% |
| Constipation |
1.7% |
| Convulsion |
1.7% |
| Crohn's Disease |
1.7% |
| Increased Appetite |
1.7% |
| Movement Disorder |
1.7% |
|
| Vomiting |
11.5% |
| Disability |
7.7% |
| Pneumocystis Jiroveci Pneumonia |
7.7% |
| Sedation |
7.7% |
| Weight Decreased |
7.7% |
| Adverse Event |
3.8% |
| Confusional State |
3.8% |
| Drug Effect Decreased |
3.8% |
| Drug Ineffective |
3.8% |
| Ileus |
3.8% |
| Incorrect Storage Of Drug |
3.8% |
| Medication Residue |
3.8% |
| Meningitis Cryptococcal |
3.8% |
| Mycobacterium Avium Complex Infection |
3.8% |
| Nausea |
3.8% |
| Pneumonia |
3.8% |
| Product Physical Issue |
3.8% |
| Somnolence |
3.8% |
| Tremor |
3.8% |
| Urticaria |
3.8% |
|
| Secondary |
| Product Used For Unknown Indication |
26.6% |
| Nausea |
11.7% |
| Nephrolithiasis |
9.4% |
| Drug Use For Unknown Indication |
6.3% |
| Drug Withdrawal Maintenance Therapy |
6.3% |
| Impaired Gastric Emptying |
6.3% |
| Vomiting |
6.3% |
| Renal Pain |
4.7% |
| Antiemetic Supportive Care |
3.9% |
| Pain |
3.9% |
| Convulsion |
3.1% |
| Cervix Carcinoma |
2.3% |
| Decreased Appetite |
2.3% |
| Breakthrough Pain |
1.6% |
| Peritoneal Mesothelioma Malignant Advanced |
1.6% |
| Anorexia |
0.8% |
| Anxiety |
0.8% |
| Brain Neoplasm |
0.8% |
| Lung Neoplasm Malignant |
0.8% |
| Myelodysplastic Syndrome |
0.8% |
|
| Toxicity To Various Agents |
26.9% |
| Disability |
15.4% |
| Asphyxia |
3.8% |
| Bradycardia |
3.8% |
| Convulsion |
3.8% |
| Head Injury |
3.8% |
| Hypoplastic Right Heart Syndrome |
3.8% |
| Overdose |
3.8% |
| Pulmonary Congestion |
3.8% |
| Respiratory Arrest |
3.8% |
| Respiratory Depression |
3.8% |
| Reversible Posterior Leukoencephalopathy Syndrome |
3.8% |
| Tetany |
3.8% |
| Treatment Failure |
3.8% |
| Vertigo Positional |
3.8% |
| Vomiting |
3.8% |
| Wound Infection Staphylococcal |
3.8% |
|
| Concomitant |
| Product Used For Unknown Indication |
28.2% |
| Drug Use For Unknown Indication |
19.0% |
| Nausea |
7.5% |
| Hiv Infection |
7.4% |
| Adverse Event |
6.0% |
| Acute Lymphocytic Leukaemia |
3.9% |
| Pain |
3.5% |
| Diffuse Large B-cell Lymphoma |
3.1% |
| Breast Cancer Metastatic |
3.1% |
| Vomiting |
2.5% |
| Non-small Cell Lung Cancer |
1.9% |
| Arthralgia |
1.7% |
| Prophylaxis |
1.7% |
| Abdominal Pain |
1.7% |
| Decreased Appetite |
1.6% |
| Multiple Sclerosis |
1.5% |
| Hypertension |
1.5% |
| Constipation |
1.4% |
| Irritable Bowel Syndrome |
1.4% |
| Hepatitis C |
1.4% |
|
| Weight Decreased |
14.0% |
| Death |
7.9% |
| Vomiting |
7.9% |
| Progressive Multifocal Leukoencephalopathy |
7.3% |
| White Blood Cell Count Decreased |
6.7% |
| Peripheral Vascular Disorder |
5.5% |
| Pneumonia |
5.5% |
| Thrombocytopenia |
4.9% |
| Febrile Neutropenia |
4.3% |
| Wound Infection Staphylococcal |
4.3% |
| Convulsion |
3.7% |
| Neutropenia |
3.7% |
| Respiratory Failure |
3.7% |
| Wound Secretion |
3.7% |
| Anxiety |
3.0% |
| Stomatitis |
3.0% |
| Syncope |
3.0% |
| Vascular Anomaly |
3.0% |
| Diarrhoea |
2.4% |
| Drug Ineffective |
2.4% |
|
| Interacting |
| Fibromyalgia |
19.2% |
| Gastric Ulcer |
19.2% |
| Product Used For Unknown Indication |
19.2% |
| Appetite Disorder |
17.3% |
| Nausea |
17.3% |
| Convulsion |
1.9% |
| Multiple Sclerosis |
1.9% |
| Pain |
1.9% |
| Trigeminal Neuralgia |
1.9% |
|
| Medication Residue |
83.3% |
| Drug Interaction |
8.3% |
| Muscular Weakness |
8.3% |
|
